According to Jefferies, Johnson & Johnson's JNJ Q1:11 results and comments point toward improving pricing, volume, and utilization trends in select divisions.
Jefferies reported that read-through is neutral-to-positive for competing companies in our universe including COV, BCR on the surgical end, and COO on the vision end. "Johnson & Johnson (JNJ, $60.46,
NC) reported Q1:11 revenue of $16.2B (+1.8% y/y operational) and EPS of $1.25 (-3.1% y/y adjusted) versus Street expectations of $15.9B and $1.26. The company raised its EPS guidance to $4.90-$5.00, up from $4.80-$4.90 to reflect F/X impacts, strong pharma performance supported by recent launches, and other operational and capital restructuring benefits. Revised guidance does not include the after-tax gain of $910M realized in the quarter as a result of litigation settlements, nor does it reflect the pending $500M payment from Merck (MRK GR, €67.56, Hold - Holford) as a result of the recent REMICADE settlement.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in